Drugs / Atipamezole
Atipamezole
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01435213 | Sep 2011 → Jan 2012 | — | University of Turku | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04942340 Comparator | May 2023 → Apr 2026 | — | University of Chicago | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atipamezole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01435213 ↗ |
| Known as | 4-(2-ethyl-2-indanyl)imidazole. | ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗ |
| Known as | Antisedan | ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗ |
| Known as | Atipamezol | ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗ |
| Known as | MPV-1248 | ChEMBL registry synonym — accepted as the source's own label CHEMBL353972 ↗ |
| Modality | Small molecule | — CHEMBL353972 ↗ |
| Route | Intravenous | “as an intravenous infusion” NCT01435213 ↗ |